Skin penetration, plasma binding, and copper-pool dynamics complicate dose extrapolation
Chronic pain is different from the sharp pain you feel right after an injury
Cagrilintide the Phase 2 monotherapy trial studied once-weekly doses of 0.3, 0.6, 1.2, 2.4, and 4.5 mg with a dose-escalation period
Alexander GolBerg MD, DO takes a different approach
Skin permeability, a dismissed necessity for anti-wrinkle peptide performance
Administration Route by Peptide Type When Injectable GHK-CU Makes Sense The injectable form provides systemic benefits that topical cannot achieve: Whole-body tissue regeneration effects Internal organ support Consistent blood levels Better bioavailability Combined with other injectable peptides When Topical Makes Sense Topical application excels for: Targeted skin treatment Hair and scalp applications Those avoiding injections Combination with skincare routines Localized wound healing For maximum benefit, some protocols use both injectable GHK-CU for systemic effects and topical copper peptides for targeted skin benefits